sp-5

Splenopentin diacetate (Splenin pentapeptide (32-36)) is a synthetic immunomodulating peptide and can reproduce the biological activities of splenin and thymic hormone thymopoietin.

(SP-5-12)-Chloro[5,10,15,20-tetrakis(4-bromophenyl)-21H,23H-porphinato(2-)-N21,N22,N23,N24]iron is a type of metal-organic framework.

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a drug-linker conjugate used in ADC (antibody-drug conjugate) applications. It consists of a linker and Exatecan.

2-MSP-5-HA-Val-Cit-PAB-Exatecan (A-24) is a drug-linker conjugate designed for use in antibody-drug conjugates (ADC). This compound consists of Exatecan and a connecting linker, and it can be applied in the synthesis of ADCs.

ASP-5854 is an adenosine A(2A) receptor antagonist with the potential to improve motor deficits in Parkinson's disease.

Sp-5,6-DCl-cBIMPS is a potent and specific activator of cAMP-dependent protein kinases (cAMP-PK) that enhances insulin release and inhibits U46619-induced activation of Rho, Gq, and G12/G13 in platelets.

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugate for ADCs, featuring a cleavable linker coupled to Exatecan. This specific compound can be conjugated to the anti-Her3 antibody [1].

Bempedoic acid (ETC1002) is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid(ETC1002) is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid(ETC1002) is a regulator of lipid and carbohydrate metabolism.

EOAI3402143 inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis. EOAI3402143 phenocopies the FAS induction and apoptotic sensitization of Usp5 knockdown and fully blocks melanoma tumor growth.

IU1-47 is an effective and specific USP14 inhibitor (IC50: 0.6 μM). IU1-47 causes tau elimination in cultured neurons. IU1-47 inhibits IsoT/USP5 (IC50: 20 μM).

NMS-P515 is an effective, orally active, and stereospecific PARP-1 inhibitor (Kd: 16 nM and an IC50: 27 nM (in Hela cells)). It has anti-tumor activity.

Enzomenib is a menin protein inhibitor that disrupts the interaction between menin and mixed lineage leukemia fusion proteins, thereby modulating transcriptional programs driven by MEN gene dysregulation and providing a targeted research tool for mechanistic studies and therapeutic exploration in hematological malignancies associated with menin-dependent oncogenic signaling.

WCY-8-67 TFA is an orally bioavailable selective USP5 inhibitor with an IC₅₀ of 1.33 μM. It induces apoptosis in vitro and inhibits the JAK/STAT3 and PI3K/AKT signaling pathways. WCY-8-67 TFA suppresses the proliferation of AE-positive acute myeloid leukemia (AML) cells, induces G1 phase cell cycle arrest, and promotes cell differentiation. It shows significant anti-leukemic activity in mouse in vivo experiments and can be used in AML research.

dsP53-285 saRNA is a small activating RNA (saRNA) that can effectively stimulate the expression of wild-type p53 by targeting its promoter. This activation leads to the inhibition of growth and metastasis in bladder cancer cells.

BMS-P5 is a specific and orally active Peptidylarginine Deiminase 4 (PAD4) inhibitor.

BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma.

P 22077 (P22077) is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM. It also inhibits the closely related USP47.

YM-543, a sodium-glucose transporter 2 (SGLT-2) inhibitor, is used potentially for the treatment of type 2 diabetes.

ASP5878 is an oral bioavailable fibroblast growth factor receptor (FGFR) inhibitor with potential anti-tumor activity.

[Asp5]-Oxytocin is the first 5-position neurohypophyseal hormone analogue with significant biological activity.

ASP5878 potently inhibited the tyrosine kinase activities of recombinant FGFR1, 2, 3, and 4 with IC50 values of 0.47, 0.60, 0.74, and 3.5 nmol/L.

USP5-IN-1 (compound 64) is a potent deubiquitinase USP5 inhibitor that binds to the USP5 ZnF-UBD with a KD of 2.8 μM and is selective over nine proteins containing structurally similar ZnF-UBD domains. Additionally, USP5-IN-1 inhibits the USP5 catalytic cleavage of a di-ubiquitin substrate [1].

YM543 free base, a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor, effectively reduces blood glucose levels and is suitable for diabetes research.

BMS-986122 is a IRAK4 Inhibitor. BMS-986126 attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity. BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus patients, suggesting that inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.